MIDAPLATIN Trademark

Trademark Overview

On Tuesday, April 2, 2013, a trademark application was filed for MIDAPLATIN with the United States Patent and Trademark Office. The USPTO has given the MIDAPLATIN trademark a serial number of 79129083. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Saturday, April 1, 2023. This trademark is owned by Midatech Limited. The MIDAPLATIN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals and medicines containing nano-particles, for use for the prevention and/or treatment of cancer, cardiovascular disorders, central nervous system disorders, acute and chronic pain, epilepsy, insomnia, infectious diseases, gastrointestinal diseases, diabetes, impotence, obesity, arthritis and autoimmune disorders, and for use as drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals allowing for controlled absorption and/or controlled release of an active ingredient following administration to human and non-human animals for the treatment of cancer, cardiovascular disorders, central nervous system disorders, acute and chronic pain, epilepsy, insomnia, infectious diseases, gastrointestinal diseases, diabetes, impotence, obesity, arthritis and autoimmune disorders; vaccines incorporating nano-particles
midaplatin

General Information

Serial Number79129083
Word MarkMIDAPLATIN
Filing DateTuesday, April 2, 2013
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateSaturday, April 1, 2023
Registration Number4523856
Registration DateTuesday, May 6, 2014
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 18, 2014

Trademark Statements

Goods and ServicesPharmaceuticals and medicines containing nano-particles, for use for the prevention and/or treatment of cancer, cardiovascular disorders, central nervous system disorders, acute and chronic pain, epilepsy, insomnia, infectious diseases, gastrointestinal diseases, diabetes, impotence, obesity, arthritis and autoimmune disorders, and for use as drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals allowing for controlled absorption and/or controlled release of an active ingredient following administration to human and non-human animals for the treatment of cancer, cardiovascular disorders, central nervous system disorders, acute and chronic pain, epilepsy, insomnia, infectious diseases, gastrointestinal diseases, diabetes, impotence, obesity, arthritis and autoimmune disorders; vaccines incorporating nano-particles

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, February 26, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameMidatech Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressGB
Party NameMidatech Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressGB
Party NameMidatech Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGB

Trademark Events

Event DateEvent Description
Sunday, October 29, 2023NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Sunday, October 29, 2023DEATH OF INTERNATIONAL REGISTRATION
Sunday, March 6, 2022TOTAL INVALIDATION PROCESSED BY THE IB
Wednesday, February 9, 2022TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Wednesday, February 9, 2022INVALIDATION PROCESSED
Tuesday, October 26, 2021TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, February 26, 2021CANCELLED SECTION 71
Friday, September 18, 2020CHANGE OF NAME/ADDRESS REC'D FROM IB
Monday, May 6, 2019COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Monday, April 30, 2018LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Thursday, April 26, 2018RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
Thursday, September 10, 2015NEW REPRESENTATIVE AT IB RECEIVED
Friday, October 10, 2014FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, September 23, 2014FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, September 23, 2014FINAL DISPOSITION PROCESSED
Wednesday, August 6, 2014FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, May 6, 2014REGISTERED-PRINCIPAL REGISTER
Tuesday, February 18, 2014NOTIFICATION PROCESSED BY IB
Tuesday, February 18, 2014OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 18, 2014PUBLISHED FOR OPPOSITION
Wednesday, January 29, 2014NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, January 29, 2014NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, January 29, 2014NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, January 16, 2014LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, January 16, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 8, 2014TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 8, 2014CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 8, 2014ASSIGNED TO LIE
Tuesday, December 17, 2013TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, August 4, 2013REFUSAL PROCESSED BY IB
Thursday, July 18, 2013NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, July 18, 2013REFUSAL PROCESSED BY MPU
Wednesday, July 17, 2013NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, July 16, 2013NON-FINAL ACTION WRITTEN
Tuesday, July 16, 2013ASSIGNED TO EXAMINER
Tuesday, May 14, 2013APPLICATION FILING RECEIPT MAILED
Friday, May 10, 2013NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, May 9, 2013SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

midaplatin disorders diseases gastrointestinal infectious epilepsy insomnia diabetes pharmaceuticals controlled human